Addition of Cediranib to Olaparib Fails to Induce Superior PFS in Platinum-Censitive Ovarian Cancer

A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news